<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275467</url>
  </required_header>
  <id_info>
    <org_study_id>2017/072</org_study_id>
    <nct_id>NCT03275467</nct_id>
  </id_info>
  <brief_title>Faecal Microbiota Transplantation in Patients With Microscopic Colitis</brief_title>
  <official_title>Faecal Microbiota Transplantation in Patients With Microscopic Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microscopic colitis (MC) is a disease with chronic inflammation of the colon that is mostly&#xD;
      diagnosed in middle-aged or elderly women. Patients suffer from chronic watery diarrhoea,&#xD;
      abdominal pain and weight loss. The aetiology of MC is still unknown but it is hypothesized&#xD;
      that MC is caused by a deregulated immune response to a luminal agent in predisposed&#xD;
      individuals, and an important role of the intestinal microbiota is suggested.&#xD;
&#xD;
      In the current proof-of-concept study, the effect of faecal microbiota transfer (FMT) in 10&#xD;
      MC patients will be evaluated. FMT consists in the infusion of suspended stool from a healthy&#xD;
      donor into the intestine of a patient with the aim to restore a disturbed intestinal&#xD;
      microbiota.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an intervention pilot study with a 12-week and an optional 6-months follow-up&#xD;
      period. It will be investigated if the infusion of suspended stool from healthy donors&#xD;
      improves the symptoms of MC patients by restoring their disturbed intestinal microbiota. This&#xD;
      procedure is known as faecal microbiota transplantation (FMT).&#xD;
&#xD;
      MC patients (n=10) will be randomised to receive FMT using stool from one of two healthy&#xD;
      donors.&#xD;
&#xD;
      At baseline, blood samples and mucosal biopsies will be obtained from the descending colon.&#xD;
      In addition, faecal samples will be collected and patients will complete symptom&#xD;
      questionnaires. The first FMT will be administered by colonoscopy, FMT 2-3 by enemas. Faecal&#xD;
      samples will be collected and questionnaires will be completed at different time points&#xD;
      during the study. The patients will be followed-up at 6 weeks, 8 weeks, 12 weeks and 6 months&#xD;
      after receiving FMT 1, however, the follow-up after 6 months will be optional. Additional&#xD;
      biopsies from the descending colon and blood samples will be collected 6 weeks after the&#xD;
      first FMT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of MC patients in remission six weeks after the first FMT.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Remission is defined as &lt;3 stools per day and a mean of less than one watery stool per day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in general health and symptom questionnaire scores</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>SHS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in general health questionnaire scores</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life questionnaire scores</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>EG-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrointestinal symptom questionnaire scores</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>GSRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hospital and anxiety depression scores</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>HADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in number and form of bowel movements</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
    <description>1-week-diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in faecal and mucosal microbiota composition</measure>
    <time_frame>faecal: 6 weeks, 8 weeks, 12 weeks, 6 months; mucosal: 6 weeks</time_frame>
    <description>16S rRNA-based next generation sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte infiltration</measure>
    <time_frame>6 weeks</time_frame>
    <description>Immunohistochemistry and flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subepithelial collagen layer</measure>
    <time_frame>6 weeks</time_frame>
    <description>Immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in immune cell composition of colonic biopsies</measure>
    <time_frame>6 weeks</time_frame>
    <description>Immunohistochemistry and flow cytometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in inflammation markers in faecal samples such as faecal calprotectin</measure>
    <time_frame>6 weeks, 8 weeks, 12 weeks, 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in metabolite profile in faecal samples and blood</measure>
    <time_frame>faecal: 6 weeks, 8 weeks, 12 weeks, 6 months; blood: 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gene expression in mucosal biopsies</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in barrier function markers in colonic biopsies</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gene expression of butyrate transporters in colonic biopsies</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in markers of inflammation and intestinal barrier function in blood</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in plasma levels of cardiovascular disease markers and platelet responsiveness and aggregation</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Microscopic Colitis</condition>
  <arm_group>
    <arm_group_label>Faecal microbiota transfer (FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspended stool from a healthy donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal microbiota transfer (FMT)</intervention_name>
    <description>Suspended stool from a healthy donor</description>
    <arm_group_label>Faecal microbiota transfer (FMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for patients:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Active MC diagnosis, defined as &gt;3 stools a day from which at least one should be&#xD;
             watery&#xD;
&#xD;
          3. Willingness to stop budesonide treatment during participation in the trial&#xD;
&#xD;
          4. Age: 18-70 years&#xD;
&#xD;
        Exclusion criteria for patients&#xD;
&#xD;
          1. Previous complicated gastrointestinal surgery&#xD;
&#xD;
          2. Malignant disease except non-melanoma skin cancer&#xD;
&#xD;
          3. Dementia, severe depression, major psychiatric disorder, or other incapacity for&#xD;
             adequate cooperation&#xD;
&#xD;
          4. C. difficile or other current gastroenteritis&#xD;
&#xD;
          5. Females who are pregnant or breast-feeding&#xD;
&#xD;
          6. Severe endometriosis&#xD;
&#xD;
          7. Antimicrobial treatment 4 weeks prior to first screening visit&#xD;
&#xD;
          8. Antimicrobial prophylaxis (eg. acne, urinary tract infection)&#xD;
&#xD;
          9. Regular consumption of probiotic products 4 weeks prior to randomization&#xD;
&#xD;
         10. Recently diagnosed lactose intolerance (less than 6 months prior to first screening&#xD;
             visit)&#xD;
&#xD;
         11. Recently diagnosed coeliac disease (less than 6 months prior to first screening visit)&#xD;
&#xD;
         12. Regular intake of NSAIDs (non steroidal anti-inflammatory drugs)&#xD;
&#xD;
         13. Abuse of alcohol or drugs&#xD;
&#xD;
         14. Any clinically significant disease/condition which in the investigator's opinion could&#xD;
             interfere with the results of the trial&#xD;
&#xD;
        Inclusion criteria for donors&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. High-butyrate producing microbiota in faecal samples&#xD;
&#xD;
          3. Age: 18-65 years&#xD;
&#xD;
        Exclusion criteria for donors&#xD;
&#xD;
          1. Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhoea or&#xD;
             constipation)&#xD;
&#xD;
          2. First degree relative with IBD&#xD;
&#xD;
          3. History of or present gastrointestinal malignancy or polyposis&#xD;
&#xD;
          4. Recent (gastrointestinal) infection (within last 6 months)&#xD;
&#xD;
          5. History of major gastrointestinal surgery (e.g. gastric bypass)&#xD;
&#xD;
          6. Eosinophilic disorders of the gastrointestinal tract&#xD;
&#xD;
          7. Current communicable disease (e.g. upper respiratory tract infection)&#xD;
&#xD;
          8. Malignant disease and/or patients who are receiving systemic anti-neoplastic agents&#xD;
&#xD;
          9. Psychiatric diseases (e.g. dementia, depression, schizophrenia, autism, Asperger&#xD;
             Syndrome) or other incapacity for adequate cooperation&#xD;
&#xD;
         10. Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple&#xD;
             sclerosis)&#xD;
&#xD;
         11. Autoimmune disease and/or patients receiving immunosuppressive medications&#xD;
&#xD;
         12. Major relevant allergies (e.g. food allergy, multiple allergies)&#xD;
&#xD;
         13. Chronic pain syndromes (e.g. fibromyalgia)&#xD;
&#xD;
         14. Chronic fatigue syndrome&#xD;
&#xD;
         15. HIV, hepatitis A, B, C or known exposure within the recent 12 months&#xD;
&#xD;
         16. Obesity (BMI&gt;30) or metabolic syndrome&#xD;
&#xD;
         17. Antimicrobial treatment or prophylaxis within the last 3 months&#xD;
&#xD;
         18. Other chronic use of drugs that may affect the microbiome, e.g. proton pump inhibitors&#xD;
&#xD;
         19. First degree relative with cardiovascular thrombosis before 50 years of age&#xD;
&#xD;
         20. Females who are pregnant or breast-feeding&#xD;
&#xD;
         21. Known clinically significant abnormal laboratory values&#xD;
&#xD;
         22. Participation in high-risk sexual behaviours&#xD;
&#xD;
         23. Abuse of alcohol or drugs&#xD;
&#xD;
         24. Tattoo or body piercing within the last 6 months&#xD;
&#xD;
         25. Travelling in countries with low hygiene or high infection risk for endemic diarrhoea&#xD;
             within the last 6 months&#xD;
&#xD;
         26. Positive stool testing for C. difficile, ova and parasites (e.g. Cyclospora, Isospora,&#xD;
             Cryptosporidium), enteric pathogens (e.g. enterohaemorrhagic E. coli, Salmonella,&#xD;
             Shigella, Yersinia, Campylobacter, Giarda antigen, amoebas)&#xD;
&#xD;
         27. Positive stool testing for multiresistant bacteria (e.g. extended-spectrum beta-&#xD;
             lactamase (ESBL) producing organisms, multi-resistant Gram-negative bacilli (MRGN) 3&#xD;
             and 4, vancomycin-resistant enterococci (VRE) or methicillin-resistant Staphylococcus&#xD;
             aureus (MRSA))&#xD;
&#xD;
         28. Calprotectin &gt; 50 μg/g of faeces&#xD;
&#xD;
         29. Positive blood testing for HIV, Hepatitis A, B, C, syphilis, Human T-lymphotropic&#xD;
             virus (HTLV), cytomegalovirus (CMV) and Epstein Barr Virus (EBV)&#xD;
&#xD;
         30. Any clinically significant disease/condition which in the investigator's opinion could&#xD;
             interfere with the results of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Brummer, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <state>Örebro County</state>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Microscopic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

